CLOSE
SITE MAP
イノベーションが
生まれる「まち」。

2019/01/10

Pitch 3-4 :Key technology for commercialization of iPS cell-based therapy- Looking for potential licensees!

【300ピクセル】S-4 iPSAcademia.png

【300ピクセル】ips academia japan.jpgMariko Awata

Manager, License, iPS Academia Japan, Inc.

[Summary]

Bringing an invention generated at research institutions to the market is not an easy job. For researchers and research institutions, it is time-consuming process to find a licensee and negotiate patent license agreement.

iPS Academia, Japan has been in this business of patents since a decade. They provide reasonable and fair terms and are quite quick in finalizing the license agreement with an experienced team.

They have a total of 140 patent families in their portfolio that span across 16 institutions, including Kyoto University and other Japanese or non-Japanese institutions. They have patented basic technologies like iPS cell generation, isolation or differentiation, as well as regenerative medicine. With many researches going on all over the world, iPSC-based regenerative medicines have gained much importance. However, there is an issue in this method for removing the pluripotent cells.

iPS Academia Japan believes that D3 compound which is invented by a promising researcher at Kyoto University is a solution for selective removal of pluripotent stem cells by using D3 for selective removal of pluripotent stem cells, a technology of Kyoto University. This technology is effective, low cost and time saving, and this enables safe clinical application and is also useful for mass production.

Nearly 180 licensees have been associated with iPS Academia; however, most of them are interested in iPS reprogramming patents. Thus, through this platform, the iPS Academia team looks forward to potential licensees.

[Mentors' comments]

 "I think it was a very nice sales pitch. I encourage you to reach out to some of the venture capital funds, maybe in Cambridge, because they often do company creation projects and are looking to license early stage intellectual property."Dr. Laura Holberger, BioLabs


[Profile]

Ms. Awata has been working as the licensing manager at iPS Academia Japan since 2010. Before joining, she worked for Intellectual Property Division and Digital Imaging Business Group at Sony Corporation. She is a graduate of Doshisha University Graduate School of Law (L.L.M.).